IL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells
Olivier Fesneau, Kimberly A. Samson, Wesley Rosales, Bretton Jones, Tarsem Moudgil, Bernard A. Fox, Venkatesh Rajamanickam, Thomas Duhen · 2024
Read IL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells by Olivier Fesneau, Kimberly A. Samson, Wesley Rosales, Bretton Jones, Tarsem Moudgil, Bernard A. Fox, Venkatesh Rajamanickam, Thomas Duhen (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11574270.txt.
Description
A brake on killer T cells turns out to be switched on by a signal meant to help them, and a 2024 study by Olivier Fesneau and co-authors traces that loop. The brake is a receptor called NKG2A, and blocking it is a live strategy for freeing anti-tumor responses.
Working with T cells from head and neck and colorectal cancers, the team found the receptor appears as killer cells mature into a tumor-reactive type. Those cells share target signatures with their receptor-free kin, so they are not a separate army. The signal IL-12 proved essential for switching the receptor on, with help from a cell-contact pair and the cell's target sensor. The findings expose a feedback loop in which a helpful signal also arms the brake.
Catalog record
| CREATOR | Olivier Fesneau, Kimberly A. Samson, Wesley Rosales, Bretton Jones, Tarsem Moudgil, Bernard A. Fox, Venkatesh Rajamanickam, Thomas Duhen |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 75 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |